Clinical Trials Logo
  1. Home
  2. Targeted Therapy
  3. NCT05983107

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Targeted Therapy Clinical Trial

Official title:
A Prospective Cohort, Open, Phase II Clinical Study of Chidamide/Everolimus Combined With Endocrine Therapy for PIK3CA Wild-type/Mutant Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer

Clinical Trial Summary

To explore the efficacy and safety of chidamide combined with endocrine in phosphoinositide-3-kinase,catalytic,alpha gene(PI3KCA) wild type hormone receptor positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients and to explore the efficacy and safety of Everolimus combined with endocrine therapy in patients with PI3KCA Mutant HR+/HER2- advanced breast cancer.

Clinical Trial Description

This study is an open, multi center, prospective cohort, and Phase II exploratory research. According to the PIK3CA gene mutation status of patients, the study is divided into two cohorts. The PIK3CA Mutant uses everolimus combined with endocrine therapy as the cohort A, and the PIK3CA wild type uses chidamide combined with endocrine therapy as the cohort B, until the disease progresses or the toxicity is intolerable. According to the judgment of the researchers, whether to enter the second stage of cross design, Queue A was cross administered with chidamide in combination with endocrine therapy. Cohort B cross used everolimus combined with endocrine until the disease progressed or the toxicity was intolerable. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05983107
Study type Interventional
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact
Status Recruiting
Phase Phase 2
Start date July 20, 2023
Completion date July 15, 2027
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05063643 - Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
Recruiting NCT06142058 - RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC
Recruiting NCT04900935 - Patient-centered, Optimal Integration of Survivorship and Palliative Care N/A
Recruiting NCT05311579 - Niraparib Plus Anlotinib for Recurrent Ovarian Cancer Phase 2
Recruiting NCT05310331 - Donafenib for Recurrent Cervical Cancer Phase 2
Recruiting NCT03185988 - Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System Phase 2
Recruiting NCT05225844 - An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal Phase 2
Completed NCT04656249 - Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer Phase 2
Recruiting NCT04821843 - Neoadjuvant Treatment Modalities in Esophageal Cancer Phase 3
Recruiting NCT04821778 - Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer Phase 3
Recruiting NCT06307249 - Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA Phase 1
Completed NCT04188847 - First-line Chemotherapy for Recurrent Cervical Cancer Phase 2
Active, not recruiting NCT02504346 - AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies Phase 2
Recruiting NCT06356584 - Sintilimab Combined With Fruquintinib/Regorafenib ± Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancer Phase 2